Respiratory Diseases
Conditions
Interventions
1:Propofol + Remifentanil Group
2:Ciprofol + Remifentanil Group
3:Remimazolam + Remifentanil Group
Sponsors
Xinjiang Medical University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.ASA II–III status with generally good or stable health, aged 18–65 years, any gender, BMI 18.5–28 kg/m²; 2.Patients undergoing non-intubated bronchoscopy with spontaneous breathing preservation (bronchial examination, biopsy, alveolar lavage, etc.), with an endoscopic procedure duration not exceeding 20 minutes; 3.Patients who voluntarily participate and sign an informed consent form; All patients enrolled in this study underwent the procedure under close anesthetic monitoring.
Exclusion criteria
Exclusion criteria: 1.Explicit refusal to participate or inability to communicate/cooperate effectively; 2. Known allergy to fat emulsions, benzodiazepines, or opioids; 3.Recent bronchial asthma attack, active massive hemoptysis, multiple pulmonary bullae, or severe superior vena cava syndrome; 4.Uncontrolled potentially life-threatening cardiovascular/respiratory conditions (e.g., acute coronary syndrome, uncontrolled severe hypertension [SBP =180 mmHg or DBP =110 mmHg] or hypotension [SBP <90 mmHg or DBP <60 mmHg], recent acute myocardial infarction, bradycardia [HR <50 bpm], severe arrhythmias, severe heart failure), poorly controlled diabetes, hepatic/renal insufficiency; acute upper respiratory infection within 2 weeks; severe airway narrowing or anticipated difficult airway management; 5. Long-term benzodiazepine use history; 6. Severe organ, neuromuscular, or psychiatric disorders; gastroesophageal reflux disease; gastroparesis; 7. Participation in other drug trials within the past 3 months; history of severe bleeding tendency or coagulation disorders; 8. Pregnancy. Patients meeting any exclusion criterion were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hypoxemia(SPO2<90%); | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety outcome(The incidence rates of hypotension, bradycardia and injection pain);Effective outcome(Anesthesia success rate, induction time, recovery time);The baseline characteristics of the three groups of patients (age, height, gender, weight, body mass index).; | — |
Countries
China
Contacts
Public ContactSuliya.Dilixiati
Xinjiang Medical University Cancer Hospital
Outcome results
None listed